Techonology and Science18 October, 20252 min read
New Blood Test Detects Over 50 Cancers Early to Speed Diagnosis and Treatment
This article is an automated aggregation of coverage from news outlets. Our editorials offer in-depth analysis curated by the NewsCord team.
Galleri blood test detects cancer-related DNA to screen over 50 cancer types early. The test accurately confirmed cancer in about 62% of positive cases in a 25,000-person trial.
7 outlets told this the same way.
New Multi-Cancer Blood Test
A new multi-cancer blood test called Galleri analyzes fragments of cancer-related DNA circulating in the blood and is being piloted in the NHS after a large North American study of roughly 25,000 adults. Reports say the test can screen for more than 50 cancers and flag a small percentage of participants as positive. The test correctly confirms cancer in a majority of those who test positive and rules out cancer in more than 99% of negatives.
“A new blood test that detects fragments of cancerous DNA circulating in the blood is being trialled by the NHS and was recently tested in a trial involving 25,000 adults in the US and Canada.”
Coverage also highlights that the test can indicate a likely tissue of origin to guide the next diagnostic steps. Early results are framed as a potential shift toward earlier detection and treatment. Experts emphasize the need for larger, randomized studies to prove a mortality benefit before widespread rollout.
Enhanced Cancer Detection with Galleri
Across studies, Galleri substantially boosted total cancers detected when added to standard screening. The test identified many cancers that currently lack routine screening options. Multiple outlets report that the test increased overall detection roughly seven-fold and found more than half of cancers at an early, more treatable stage.
Coverage also notes strong performance in pinpointing likely tissue of origin, with about 90–92% accuracy. The test highlights detection in cancers like ovarian, liver, stomach, bladder, and pancreatic, which are areas where screening gaps are common. One report specifies that trials found 133 cancers with Galleri versus 20 via current screenings, illustrating both relative and absolute gains reported across sources.
Test Accuracy and Evaluation
Accuracy and false-positive rates are framed differently across reports. Several outlets highlight high rule-out accuracy—over 99%—and a very low false-positive rate, while also noting a positive predictive value around 62%.
“The test is highly accurate in ruling out cancer (99.6%) and can identify the cancer’s tissue of origin in 92% of cases, potentially speeding diagnosis and reducing additional tests.”
Some coverage explicitly mentions concerns about false positives and overdiagnosis and urges randomized trials with mortality outcomes before broad adoption. Together, these details portray a test that is specific and promising, yet still in need of definitive evidence on clinical endpoints like reductions in late-stage diagnoses and deaths.
NHS Cancer Screening Trials
Trials and rollout plans for the Galleri test are advancing on multiple fronts. The NHS is piloting Galleri widely in England, including in pharmacies and mobile units. Results from these pilots are expected next summer.
Investigators plan to present full trial results at a European oncology conference. More data from a large NHS study will be released next year. Some sources note the NHS could expand testing to one million people if the evidence is favorable.
Annual screening for people aged 50 and over is a potential use case. The developer, Grail, is also targeting US regulatory approval within roughly the next couple of years.
Public Health Perspectives on Cancer Testing
Public-health framing varies across coverage. Some emphasize a systems-level pivot toward prevention, arguing the test could reduce late-stage diagnoses and deaths and help shift the NHS from treatment to prevention. Others stress persistent barriers such as low awareness of early warning signs among the public and health workers.
“Health officials see the test as a key tool in shifting from cancer treatment to prevention as part of the UK’s 10 Year Health Plan.”
Even optimistic reports repeatedly underline that randomized studies must still show reductions in cancer mortality before routine adoption. This underscores both promise and caution in equal measure.
